Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program

作者：Jean Addington, Lu Liu, Amy Braun, Andrea M. Auther, Monica E. Calkins, Barbara A. Cornblatt, Cheryl M. Corcoran, Paolo Fusar‐Poli, Melissa Kerr, Catalina Mourgues, Ángela Núñez, Dominic Oliver, Gregory P. Strauss, Barbara C. Walsh, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Ricardo E. Carrión, Eric Chen, Jimmy Choi, Michael J. Coleman, Philippe Conus, Covadonga M. Díaz‐Caneja, Dominic Dwyer, Lauren M. Ellman, Masoomeh Faghankhani, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Grace R. Jacobs, Joseph Kambeitz, Lana Kambeitz‐Ilankovic, Matcheri S. Keshavan, Sung‐Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Kathryn E. Lewandowski, Daniel Mamah, Patricia Marcy, Daniel H. Mathalon, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Nora Penzel, Jesús Pérez, Diana O. Perkins, Albert R. Powers, Jack D. Rogers, Fred W. Sabb, Jason Schiffman, Jai Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Andrew Thompson, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Jijun Wang, Heather M. Wastler, Alana Wickham, Inge Winter-van Rossum, Daniel H. Wolf, Sylvain Bouix, Ofer Pasternak, René S. Kahn, Carrie E. Bearden, John M. Kane, Patrick D. McGorry, Kate Buccilli, Barnaby Nelson, Martha E. Shenton, Scott W. Woods, the Accelerating Medicines Partnership® -Schizophrenia, Alison R. Yung · 发表于：Schizophrenia · 年份：2025 · DOI：10.1038/s41537-025-00556-7 · 被引用次数：9 · 研究领域：Schizophrenia research and treatment、Mental Health and Psychiatry、Bipolar Disorder and Treatment

SCZ) Clinical Ascertainment and Outcome Measures Team aimed to establish a harmonized clinical assessment protocol across these two research networks and to define ascertainment criteria and primary and secondary endpoints. In addition to developing the assessment protocol, the goals of this aspect of the AMP SCZ project were: (1) to implement and monitor clinical training, ascertainment of participants, and clinical assessments; (2) to provide expert clinical input to the Psychosis Risk Evaluation, Data Integration and Computational Technologies: Data Processing, Analysis, and Coordination Center (PREDICT-DPACC) for data collection, quality control, and preparation of data for the analysis of the clinical measures; and (3) to provide ongoing support to the collection, analysis, and reporting of clinical data. This paper describes the (1) protocol clinical endpoints and outcomes, (2) rationale for the selection of the clinical measures, (3) extensive training of clinical staff, (4) preparation of clinical measures for a multisite study which includes several sites where English is not the native language; and (5) the assessment of measure stability over time in the AMP SCZ observational study comparing clinical ratings at baseline and at the 2-month follow up. Watch Dr. Jean Addington discuss her work and this article: https://vimeo.com/1040425281 .